{"id":"mk0831","safety":{"commonSideEffects":[{"rate":null,"effect":"Lymphopenia"},{"rate":null,"effect":"Infections"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CCR4 is highly expressed on regulatory T cells (Tregs) and activated effector T cells. By blocking CCR4, MK0831 depletes Tregs from tumors and enhances anti-tumor immune responses. This mechanism aims to shift the immune balance toward anti-tumor immunity, potentially enhancing checkpoint inhibitor efficacy.","oneSentence":"MK0831 is a selective antagonist of the chemokine receptor CCR4 that reduces the recruitment and activation of T regulatory cells and other immune cells to the tumor microenvironment.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:21:42.771Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (in combination with checkpoint inhibitors)"}]},"trialDetails":[{"nctId":"NCT06797674","phase":"PHASE1","title":"A Study of the Effect Efavirenz on the Plasma Levels of MK-7602 in Healthy Participants (MK-7602-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-02-10","conditions":"Healthy","enrollment":34},{"nctId":"NCT00543530","phase":"PHASE3","title":"Pediatric Expanded Access Program-Oral Solution (0831-908)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2001-03","conditions":"HIV Infections","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MK0831","genericName":"MK0831","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MK0831 is a selective antagonist of the chemokine receptor CCR4 that reduces the recruitment and activation of T regulatory cells and other immune cells to the tumor microenvironment. Used for Advanced or metastatic solid tumors (in combination with checkpoint inhibitors).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}